SEC Form SC 13G/A filed by Protagonist Therapeutics Inc. (Amendment)

$PTGX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $PTGX alert in real time by email
SC 13G/A 1 p24-0672sc13ga.htm PROTAGONIST THERAPEUTICS, INC.

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G/A
 
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
 

Protagonist Therapeutics, Inc.

(Name of Issuer)
 

Common Stock, par value $0.00001 per share

(Title of Class of Securities)
 

74366E102

(CUSIP Number)
 

December 31, 2023

(Date of Event Which Requires Filing of this Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
¨ Rule 13d-1(b)
ý Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 7 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 74366E10213G/APage 2 of 7 Pages

 

1

NAME OF REPORTING PERSON

 

Point72 Asset Management, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨

(b)x

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,613,453

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,613,453

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,613,453

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

4.5%

12

TYPE OF REPORTING PERSON

PN

         

 

 

CUSIP No. 74366E10213G/APage 3 of 7 Pages

 

 

1

NAME OF REPORTING PERSON

 

Point72 Capital Advisors, Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨

(b)x

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,613,453

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,613,453

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,613,453

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

4.5%

12

TYPE OF REPORTING PERSON

CO

         

 

 

CUSIP No. 74366E10213G/APage 4 of 7 Pages

 

 

1

NAME OF REPORTING PERSON

 

Steven A. Cohen

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨

(b)x

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,613,453

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,613,453

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,613,453

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

4.5%

12

TYPE OF REPORTING PERSON

IN

         

 

 

CUSIP No. 74366E10213G/APage 5 of 7 Pages

 

 

Item 1(a). Name of Issuer.
  Protagonist Therapeutics, Inc. (the “Issuer”).
Item 1(b). Address of Issuer’s Principal Executive Offices.
  7707 Gateway Boulevard, Suite 140, Newark, California 94560-1160.

 

Item 2(a). Name of Person Filing.
 

This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.00001 per share (“Shares”), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.

 

Item 2(b). Address of Principal Business Office.
  The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

 

Item 2(c). Place of Organization.
  Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Mr. Cohen is a United States citizen.

 

Item 2(d). Title of Class of Securities.
  Common Stock, par value $0.00001 per share.
   
Item 2(e). CUSIP Number.
  74366E102

 

Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
  Not applicable.

 

Item 4. Ownership.
 

The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2023.

 

Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc.The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

 

CUSIP No. 74366E10213G/APage 6 of 7 Pages

 

 

Item 5. Ownership of Five Percent or Less of a Class.
  If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].
   
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
  See Item 2(a).
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
  Not applicable.
   
Item 8. Identification and Classification of Members of the Group.
  Not applicable.
   
Item 9. Notice of Dissolution of Group.
  Not applicable.

 

Item 10. Certification.
  By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
   

 

 

CUSIP No. 74366E10213G/APage 7 of 7 Pages

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Date: February 14, 2024  
  POINT72 ASSET MANAGEMENT, L.P.
   
  By:  /s/ Jason M. Colombo
  Name:  Jason M. Colombo
 

Title: Authorized Person

 

 

  POINT72 CAPITAL ADVISORS, INC.
   
  By:  /s/ Jason M. Colombo
  Name:  Jason M. Colombo
  Title:    Authorized Person
   
  STEVEN A. COHEN
   
  By:  /s/ Jason M. Colombo
  Name:  Jason M. Colombo
  Title:    Authorized Person

 

Get the next $PTGX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PTGX

DatePrice TargetRatingAnalyst
12/6/2024$47.00Neutral
Goldman
12/6/2024$62.00Outperform
BMO Capital Markets
11/5/2024$58.00Outperform
Wedbush
9/24/2024$65.00Buy
TD Cowen
9/9/2024$60.00Buy
Truist
10/30/2023$32.00Overweight
CapitalOne
5/25/2023$30.00 → $40.00Buy
Jefferies
8/25/2022$21.00Mkt Outperform
JMP Securities
More analyst ratings

$PTGX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

    − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Protagonist Therapeutics Reports Granting of Inducement Awards

    NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter. Dr. Yeilding served in a consultant role as the Company's Chief Scientific Advisor from August 1, 2024 through January 1, 2025. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.Dr. Yeilding received options to purchase 38,520 sh

    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

    NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a company overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 12-16, 2025 in San Francisco, CA. The Company will also participate in one-on-one meetings.43rd Annual J.P. Morgan Healthcare Conference - January 12-16, 2025Format: Company PresentationDay/Time: Tuesday, January 14 at 8:15AM PTWebcast: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58274-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=trueIf you are interested in meeting

    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PTGX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PTGX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PTGX
SEC Filings

See more

$PTGX
Leadership Updates

Live Leadership Updates

See more
  • Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

    Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I spaceNEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery,

    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Protagonist Therapeutics Set to Join S&P SmallCap 600

    NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 3, 2024 S&P SmallCap 600 Addition Protagonist Therapeutics PTGX Health Care S&P SmallCap 600 Deletion Encore Wire WIRE Industrials For more information a

    $PTGX
    $SPGI
    $WIRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
  • Turnstone Biologics Appoints William Waddill to its Board of Directors

    SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

    $ANNX
    $ARWR
    $PTGX
    $TSBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$PTGX
Financials

Live finance-specific insights

See more
  • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

    − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

    Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases."We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL

    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

    Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information belowNEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results.Conference Call and Webcast DetailsThe dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are:US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274The webcast link for the event can

    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PTGX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more